April 1, 2008 (v1)
Journal article
No description
Uploaded on: December 4, 2022
-
-
April 2021 (v1)Journal article
Dermatofibrosarcoma protuberans (DFSP) is a soft-tissue sarcoma characterized by a high risk of local infiltration. The identification of the COL1A1-PDGFB t(17;22) translocation activating the PDGF pathway led to the use of imatinib in unresectable DFSP, with a response rate of 36-80%. Pazopanib is a multitarget tyrosine kinase inhibitor...
Uploaded on: December 3, 2022 -
June 15, 2010 (v1)Journal article
AIMS: The treatment of dermatofibrosarcoma protuberans (DFSP) involves wide local excision with frequent need for reconstructive surgery. A t(17;22) translocation resulting in COL1A1-PDGFB fusion is present in >95% of cases. Certain patient observations and a report on nine patients suggest that imatinib mesylate, targeting platelet-derived...
Uploaded on: December 4, 2022 -
November 2022 (v1)Journal article
Purpose: Mitogen-activating protein kinase inhibitors (MAPKis) are largely used in V600E/K BRAF–mutated metastatic melanomas, but data regarding effectiveness of targeted therapy in patients with rare BRAF mutations and molecular description of these infrequent mutations are scarce. Patients and methods: A multicenter study was conducted on...
Uploaded on: March 31, 2023